CompletedNot Applicable

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.

United States230 participantsStarted 2024-06-21

Plain-language summary

Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking. The EXOMIC study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to detect occult metastasis preoperatively in patients with resectable ICC.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically confirmed ICC (clinical stage I-III). * Undergoing curative-intent hepatectomy. * Availability of preoperative pasma or serum sample (≥200 µL). * Standard staging imaging completed per institutional protocol. * Written informed consent. Exclusion Criteria: * Extrahepatic cholangiocarcinoma or gallbladder cancer. * Synchronous non-ICC malignancy. * Inadequate clinical follow-up. * Inability to consent.

What they're measuring

Recurrence Free Survival

Timeframe: 3 years

Trial details

NCT IDNCT07224737

SponsorCity of Hope Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-01-18

View on ClinicalTrials.gov More Intrahepatic Cholangiocarcinoma (Icc) trials